AIM To prepare valaciclovir polybutylcyan_ oacrylate nanoparticles (VACV PBCA NP) with liver targeting and hepatocyte permeable characteristics. METHODS Emulsion polymerization method was employed to prepare V...AIM To prepare valaciclovir polybutylcyan_ oacrylate nanoparticles (VACV PBCA NP) with liver targeting and hepatocyte permeable characteristics. METHODS Emulsion polymerization method was employed to prepare VACV PBCA NP. The formula and preparation conditions were optimized by using the uniform design. The organ distribution of the intravenously injected VACV PBCA NP and VACV in animal was determined using HPLC. The hepatocytes permeability of VACV PBCA NP was demonstrated by cell uptake experiment in vitro . RESULTS The drug loading and the drug embedding ratio of VACV PBCA NP were 11 20% and 84 85% respectively, with an average diameter of 104 77nm ± 11 78nm . The releasing characteristics in vitro fitted the two phase kinetics. 74 49% of the drug was found to localize in the liver 15min after the administration of VACV PBCA NP in the mice. Compared with VACV, VACV PBCA NP showed distinct characteristic of sustained release in vivo and the drug entering hepatocytes were also greatly increased. CONCLUSION VACV PBCA NP has the char_ acteristic of liver targeting and can increase the permeability of VACV to hepatocytes.展开更多
文摘AIM To prepare valaciclovir polybutylcyan_ oacrylate nanoparticles (VACV PBCA NP) with liver targeting and hepatocyte permeable characteristics. METHODS Emulsion polymerization method was employed to prepare VACV PBCA NP. The formula and preparation conditions were optimized by using the uniform design. The organ distribution of the intravenously injected VACV PBCA NP and VACV in animal was determined using HPLC. The hepatocytes permeability of VACV PBCA NP was demonstrated by cell uptake experiment in vitro . RESULTS The drug loading and the drug embedding ratio of VACV PBCA NP were 11 20% and 84 85% respectively, with an average diameter of 104 77nm ± 11 78nm . The releasing characteristics in vitro fitted the two phase kinetics. 74 49% of the drug was found to localize in the liver 15min after the administration of VACV PBCA NP in the mice. Compared with VACV, VACV PBCA NP showed distinct characteristic of sustained release in vivo and the drug entering hepatocytes were also greatly increased. CONCLUSION VACV PBCA NP has the char_ acteristic of liver targeting and can increase the permeability of VACV to hepatocytes.
